Compare PHAT & KRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAT | KRSP |
|---|---|---|
| Founded | 2018 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 590.6M | 486.7M |
| IPO Year | 2019 | 2025 |
| Metric | PHAT | KRSP |
|---|---|---|
| Price | $6.92 | $10.46 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $20.09 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 129.5K |
| Earning Date | 10-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $80.58 | N/A |
| Revenue Next Year | $56.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $6.52 | $10.21 |
| 52 Week High | $18.31 | $11.89 |
| Indicator | PHAT | KRSP |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 42.60 |
| Support Level | $6.91 | $10.34 |
| Resistance Level | $9.74 | $10.52 |
| Average True Range (ATR) | 0.37 | 0.12 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 47.08 | 1.85 |
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Rice Acquisition Corp 3 is a blank check company.